Bausch Health offers deep statistical value — a 1.2x forward P/E and approximately 7-to-1 risk/reward in the buyer's favor — but is in a confirmed technical downtrend with a death cross in place, mixed earnings execution, and extreme revenue concentration in a single product; the asymmetric setup favors patience for a catalyst rather than active accumulation into the breakdown.
Thesis pillars
- Fcf Generation Cushions Gaap Losses→Stable
- Product Concentration Binary Risk↑Improving
- Deep Value Asymmetric Upside↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Bausch Health Companies Inc. (BHC) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $6.76, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%).
Bausch Health develops specialty pharmaceuticals and medical devices across five segments—Salix (GI/hepatology), International, Solta Medical, Diversified, and Bausch + Lomb (eye health)—marketed in approximately 90 countries. Revenues totaled $10,266 million in 2025; Xifaxan®... Read more
Hold if already holding. Not a fresh buy at $6.76, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 54d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-09-04Recent Developments — Bausch Health Companies Inc.
Latest news
- NEWS Bausch Health Share Price | BHC Stock - Investing.com UK — Investing.com UK neutral
- NEWS Bausch: Q2 Earnings Snapshot - KING5.com — KING5.com neutral
- NEWS Bausch: Q2 Earnings Snapshot - king5.com — king5.com neutral
- NEWS Bausch Health surges on earnings beat and raised guidance By Investing.com - Investing.com UK — Investing.com UK positive
- NEWS Bausch Health Rises After Q2 Earnings, Revenue Beat Estimates - Moomoo — Moomoo positive
Generated 2026-09-04T13:27:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXifaxan®85%10-K Item 1: 'Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues.'
- HIGHProductArestin®95%10-K Item 1: 'Arestin® ... represents approximately 95% of Dentistry revenues'
- MEDIUMSupplierlimited number of sources for finished products and raw materials10-K Item 1A: 'our dependence on a limited number of sources for certain of our finished products and raw materials'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $6.76, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $6.94 (+2.7%), stop $6.29 (−7.5%), A.R:R -0.3:1. Score 6.4/10, moderate confidence.
Take-profit target: $6.94 (-3.5% upside). Target $6.94 (+2.7%), stop $6.29 (−7.5%), A.R:R -0.3:1. Stop-loss: $6.29.
Concentration risk — Product: Xifaxan® (85.0%); Concentration risk — Product: Arestin® (95.0%); Analyst target reached - limited upside remaining.
Bausch Health Companies Inc. trades at a P/E of N/A (forward 1.6). TrendMatrix value score: 8.5/10. Verdict: Hold.
8 analysts cover BHC with a consensus score of 2.4/5. Average price target: $8.
What does Bausch Health Companies Inc. do?Bausch Health develops specialty pharmaceuticals and medical devices across five segments—Salix (GI/hepatology),...
Bausch Health develops specialty pharmaceuticals and medical devices across five segments—Salix (GI/hepatology), International, Solta Medical, Diversified, and Bausch + Lomb (eye health)—marketed in approximately 90 countries. Revenues totaled $10,266 million in 2025; Xifaxan® drives approximately 85% of Salix segment sales. The company holds approximately 88% of publicly traded Bausch + Lomb, which it is pursuing to separate.